A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Dose Levels of Pumosetrag in Patients With Symptoms Associated With Gastroesophageal Reflux Disease (GERD) Receiving a Standard Refluxogenic Meal.

Trial Profile

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Dose Levels of Pumosetrag in Patients With Symptoms Associated With Gastroesophageal Reflux Disease (GERD) Receiving a Standard Refluxogenic Meal.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Pumosetrag (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Nov 2011 Results presented at the 76th Annual Scientific Meeting of the American College of Gastroenterology.
    • 20 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Sep 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top